SCHEMBL6046818

SCHEMBL6046818

CCn1c(=O)c2c(C)[nH]nc2c2cc(-c3ccc(CN4C(C)(C)CCCC4(C)C)s3)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 11/20 0.42
KCNH2 Q12809 2/20 0.36
METAP2 P50579 1/20 0.35
AURKA O14965 1/20 0.33
KDR P35968 1/20 0.33
AURKB Q96GD4 1/20 0.33
PDE4A P27815 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33
PDE4D Q08499 2/20 0.33
PARG Q86W56 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
ALOX15 P16050 1/20 0.31
GFER P55789 1/20 0.31
HSD17B10 Q99714 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2B Q13224 1/20 0.31
PRKCQ Q04759 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6046709 0.88 CHEK1 (0.44) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046756 0.86 CHEK1 (0.44) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046693 0.83 CHEK1 (0.42) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046764 0.83 CHEK1 (0.53) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046867 0.83 CHEK1 (0.43) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046812 0.83 CHEK1 (0.43) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046825 0.83 CHEK1 (0.40) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046710 0.82 CHEK1 (0.42) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046730 0.81 CHEK1 (0.54) CHEK1KCNH2METAP2AURKAKDR
SCHEMBL6046776 0.81 CHEK1 (0.46) CHEK1KCNH2METAP2AURKAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060035920-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035920-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885KCNH2 3052/4885METAP2 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.